Literature DB >> 9543106

C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group.

V Gudnason1, D Stansbie, J Scott, A Bowron, V Nicaud, S Humphries.   

Abstract

A common polymorphism has been described in the methylenetetrahydrofolate reductase (MTHFR) gene, substituting an alanine (A) for a valine (V), where the V allele results in a thermolabile enzyme with reduced activity. This polymorphism is easily detectable by PCR amplification and digestion with HinfI restriction enzyme. We describe the use of the MADGE high throughput genotyping system for rapid typing of this polymorphism. Seven hundred and eighty five individuals participating in the European Atherosclerosis Research Study II (EARS II), aged 22-25 from 14 universities in 12 countries across Europe were genotyped for this polymorphism. The frequency of the V allele was 0.32 overall (95% CI; 0.30-0.35), but was significantly lower in the Baltic countries (0.23; 95% CI; 0.19-0.28) compared with the other regions of Europe (0.37; 95% CI; 0.32-0.38) (P < 0.001). Individuals homozygous for the V allele had statistically significant (P < 0.001) higher plasma homocysteine (16.5 micromol/l) compared with those heterozygous for an A allele (10.4 micromol/l) or homozygous for an A allele (10.0 micromol/l). This effect was seen in all countries and regions of Europe. Mean plasma homocysteine levels were significantly higher in the South compared to the Baltic, UK and Middle regions (P = 0.001), but this difference was not explained by the difference in the frequency of the V allele in the samples. This polymorphism explained 12.3% of the total sample variance in plasma homocysteine, other measured factors (smoking, alcohol consumption, systolic blood pressure, physical activity) explained 0.7%. This study demonstrates the large and consistent impact of the thermolabile MTHFR variant on plasma homocysteine levels in different European populations, and shows a regional difference in the levels of homocysteine that must be explained by other genetic or environmental factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543106     DOI: 10.1016/s0021-9150(97)00237-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  26 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men.

Authors:  Mohammad Reza Safarinejad; Nayyer Shafiei; Shiva Safarinejad
Journal:  Med Oncol       Date:  2010-10-29       Impact factor: 3.064

3.  Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer.

Authors:  E Vairaktaris; C Yapijakis; P Kessler; A Vylliotis; J Ries; J Wiltfang; S Vassiliou; S Derka; F W Neukam
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-20       Impact factor: 4.553

Review 4.  Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis.

Authors:  Kai Li; Yong ping Hu; Zecheng Yang; Tongxin Sun
Journal:  Tumour Biol       Date:  2013-05-07

5.  Prevalence of the methylenetetrahydrofolate reductase 677C > T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors.

Authors:  M Guillén; D Corella; O Portolés; J I González; F Mulet; C Sáiz
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

6.  Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults.

Authors:  C F Skibola; M T Smith; E Kane; E Roman; S Rollinson; R A Cartwright; G Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  Serum total homocysteine and coronary heart disease: prospective study in middle aged men.

Authors:  P H Whincup; H Refsum; I J Perry; R Morris; M Walker; L Lennon; A Thomson; P M Ueland; S B Ebrahim
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

Review 8.  Homocysteine and coronary risk.

Authors:  N Seshadri; K Robinson
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

9.  Methylenetetrahydrofolate reductase C677T gene polymorphism and colorectal cancer risk: A case-control study.

Authors:  Guancheng Yin; Hanxin Ming; Xiao Zheng; Yi Xuan; Jianwei Liang; Xing Jin
Journal:  Oncol Lett       Date:  2012-05-30       Impact factor: 2.967

10.  Physical activity is inversely associated with total homocysteine levels, independent of C677T MTHFR genotype and plasma B vitamins.

Authors:  Rachel Dankner; Angela Chetrit; Gie Ken Dror; Ben-Ami Sela
Journal:  Age (Dordr)       Date:  2007-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.